Format

Send to

Choose Destination
Biomimetics (Basel). 2018 Mar 7;3(1). pii: E4. doi: 10.3390/biomimetics3010004.

Targeting Early Dementia: Using Lipid Cubic Phase Nanocarriers to Cross the Blood⁻Brain Barrier.

Author information

1
Cavitation-Control Technology Inc., Farmington, CT 06032, USA. cavcon@ntplx.net.

Abstract

Over the past decades, a frequent co-morbidity of cerebrovascular pathology and Alzheimer's disease has been observed. Numerous published studies indicate that the preservation of a healthy cerebrovascular endothelium can be an important therapeutic target. By incorporating the appropriate drug(s) into biomimetic (lipid cubic phase) nanocarriers, one obtains a multitasking combination therapeutic, which targets certain cell surface scavenger receptors, mainly class B type I (i.e., SR-BI), and crosses the blood⁻brain barrier. This targeting allows for various cell types related to Alzheimer's to be simultaneously searched out for localized drug treatment in vivo.

KEYWORDS:

Alzheimer’s disease; SR-BI; biomimetic nanocarriers; blood–brain barrier; dementia; drug targeting; lipid cubic phase; nanoemulsion; scavenger receptors

Conflict of interest statement

The authors declare no conflict of interest. J.S.D. is employed at Cav-Con Inc.

Publication type

Publication type

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center